Equities

KPC Pharmaceuticals Inc

600422:SHH

KPC Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)12.06
  • Today's Change-0.24 / -1.95%
  • Shares traded11.12m
  • 1 Year change-28.85%
  • Beta0.9606
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy4
Outperform6
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 2 analysts offering 12 month price targets for KPC Pharmaceuticals Inc have a median target of 22.44, with a high estimate of 24.20 and a low estimate of 20.68. The median estimate represents a 83.03% increase from the last price of 12.26.
High97.4%24.20
Med83.0%22.44
Low68.7%20.68

Dividends

In 2023, KPC Pharmaceuticals Inc reported a dividend of 0.20 CNY, which represents a 25.00% increase over last year. The 3 analysts covering the company expect dividends of 0.23 CNY for the upcoming fiscal year, an increase of 15.00%.
Div growth (TTM)25.00%
More ▼

Earnings history & estimates in CNY

KPC Pharmaceuticals Inc reported annual 2023 earnings of 0.590 per share on Mar 21, 2024.
Average growth rate+0.98%
More ▼

Revenue history & estimates in CNY

KPC Pharmaceuticals, Inc. had revenues for the full year 2023 of 7.70bn. This was 6.99% below the prior year's results.
Average growth rate+2.24%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.